Ventavis Generic: When Will Generic Iloprost Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Ventavis Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? July to December 2026 A 6-month window Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the brand’s protection end? None listed No patent or exclusivity on file
- Can you buy a generic today? Not yet No company lists one for sale
Generic iloprost is expected to be available between July and December 2026. None is for sale yet.
Why July to December 2026?
A generic maker is expected to launch around then. We rate it probable: more likely than not, but it can still move.
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. One company has applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 31% less once one company sold a generic. See the price pattern
What should I do now?
Keep taking Ventavis as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Ventavis by the Numbers
- Reason
- Launch expectedA generic maker is expected to launch around then.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Low 1 company has filed
- Brand sales
- Sales not reported
- FDA approved 2004 December 2004 FDA Orange Book
- Patents listed 0 none listed FDA Orange Book
Ventavis’s Road to a Generic
Ventavis has had the market to itself since the FDA approved it in December 2004 (Actelion Pharmaceuticals US Inc).
The first generic of Ventavis is expected between July and December 2026.
Why that month: a generic maker is expected to launch around then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Who Is Lined Up to Make Generic Iloprost
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
One company has applied to the FDA to make generic iloprost.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for this one yet, so the company is not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
Approved by the FDA
Not yet. The FDA has not approved a generic iloprost. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic iloprost for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Ventavis Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Ventavis, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
Ventavis Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 20MCG/2ML (10MCG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | Solution | Inhalation | December 2004 | Discontinued |
| 10MCG/ML (10MCG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | Solution | Inhalation | December 2005 | Discontinued reference product |
| 20MCG/ML (20MCG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | Solution | Inhalation | August 2009 | Discontinued reference product |
Source: FDA Orange Book, Actelion Pharmaceuticals US Inc. Listed for sale today by Actelion Pharmaceuticals US, Inc. (FDA NDC Directory).
Ventavis NDC Codes and Packages
Each Ventavis package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 66215-0302-30 | 10 ug/mL solution | carton of 30 ampules of 1 mL | Actelion Pharmaceuticals US, Inc. |
| 66215-0303-30 | 20 ug/mL solution | carton of 30 ampules of 1 mL | Actelion Pharmaceuticals US, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Ventavis’s own FDA approval (NDA 21779) are listed, never a generic. Some codes belong to companies that repackage Ventavis: it is the same medicine in a different package.
What a Generic Ventavis Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Ventavis as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Ventavis”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Ventavis
Is there a generic for Ventavis right now?
No. As of October 9, 2026 no generic iloprost is listed for sale in the FDA NDC Directory.
When will Ventavis go generic?
July to December 2026 is the expected window, and that is probable but not certain. A generic maker is expected to launch around then.
Will generic iloprost be the same as Ventavis?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. One company has applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 31% less once one company sold a generic. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Ventavis?
Not yet. The FDA Orange Book lists no approved generic version of Ventavis.
When does the Ventavis patent expire?
No patents are listed for Ventavis in the FDA Orange Book. Why that month: a generic maker is expected to launch around then.
Changes to This Projection
- First generic expected July to December 2026 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- XtandiEnzalutamideJuly to September 2027
- TechnegasTechnetium TC-99M Labeled CarbonFebruary 2031
- BraftoviEncorafenibJune 2032
- FilsuvezBirch triterpenes2035 to 2036
- LifyorliRelacorilant2039 to 2040
- PhyragoDasatinibJanuary 2041
About Ventavis
- Generic name iloprost
- How it is taken Inhaled
- Company Actelion Pharmaceuticals US Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with V
- Have a question? A pharmacist answers, free. Ask about Ventavis
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.